IMvigor130 data suggests atezolizumab plus chemotherapy delays progression in urothelial carcinoma, with potential survival benefit seen in PD-L1 subgroup treated with monotherapy.
Lantern will use its AI platforms and NCI's omics datasets to identify and validate predictive genomic signatures for drugs it is developing.
A collection of biomarker- and genomic testing-driven precision oncology research presented at the European Society of Medical Oncology Congress.
Based on the strength of the data from the ClarIDHy trial, Agios Pharmaceuticals is aiming to submit for regulatory approval with the FDA by year end.
Men with metastatic castration-resistant prostate cancer who had mutations in genes like BRCA1 and BRCA2 benefited from treatment with olaparib.
The new analysis has confirmed earlier evidence that patients with high Oncotype DX risk scores appear to benefit significantly from added chemotherapy.
Two studies showed that the addition of abemaciclib or ribociclib to fulvestrant improved overall survival in HR-positive, HER2-negative breast cancer patients.
Two KEYNOTE studies showed TMB may have some utility in determining which NSCLC patients should get pembrolizumab, while three others showed no utility.
The team identified six independent DNA methylation blocks that could potentially help to predict the formation of central nervous system metastases in lung cancer.
Results from the CheckMate-227 trial provided evidence for the use of nivolumab and ipilimumab in combination, while the FLAURA study focused on osimertinib.